FAKTOR-OPTIONSSCHEIN - BIOMERIEUX Stock

Certificat

DE000MG156M4

Real-time Bid/Ask 03:14:30 2024-07-04 am EDT
4.29 EUR / 4.33 EUR +8.84% Intraday chart for FAKTOR-OPTIONSSCHEIN - BIOMERIEUX
Current month+11.24%
1 month-32.77%
Date Price Change
24-07-03 3.96 +3.66%
24-07-02 3.82 -0.52%
24-07-01 3.84 +7.87%
24-06-28 3.56 -10.33%
24-06-27 3.97 -10.18%

Delayed Quote Börse Stuttgart

Last update July 03, 2024 at 02:51 pm EDT

More quotes

Static data

Product typeExotic Products
Buy / SellCALL
Underlying BIOMÉRIEUX
Issuer Morgan Stanley
WKN MG156M
ISINDE000MG156M4
Date issued 2024-03-27
Strike 75.22
Maturity Unlimited
Parity 3.81 : 1
Emission price 10
Emission volume N/A
Settlement cash
Currency EUR

Technical Indicators

Highest since issue 12.7
Lowest since issue 3.5
Spread -0.31
Spread %7.73%

Company Profile

bioMérieux designs, develops, produces, and sells systems used in clinical practice to diagnose infectious diseases (including HIV, tuberculosis, and respiratory infections), cancers, and cardiovascular pathologies based on a biological sample (blood, saliva, urine, etc.). Net sales break down by sector of application as follows: - medical applications (84.4%): in industry, microbiological testing of samples from finished products, materials during the manufacturing process, or the environment, primarily in the food-processing, pharmaceutical, and cosmetics sectors; - industrial applications (15.6%). The group's diagnostic systems consist of three elements with related services: reagents, instruments (or platforms or analyzers), software, and services. Net sales are distributed geographically as follows: Europe/Middle East/Africa (32.4%), North America (44.1), Asia/Pacific (17.3%) and Latin America (6.2%).
Sector
-
More about the company

Ratings for bioMérieux

Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings

Consensus: bioMérieux

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
13
Last Close Price
90.25 EUR
Average target price
113.5 EUR
Spread / Average Target
+25.74%
Consensus